Basket cover image
15 handpicked stocks

Hollywood's New Power Player

The FCC's approval of the $8 billion Paramount-Skydance merger creates a new powerhouse in the media and entertainment industry. This major consolidation is expected to catalyze further M&A activity, presenting investment opportunities among other media companies and content producers poised for growth.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 25

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

WBD

WARNER BROS DISCOVERY INC

WBD

Current price

$11.56

DIS

The Walt Disney Company

DIS

Current price

$116.27

FOXA

Fox Corporation Class A Shares

FOXA

Current price

$58.15

About This Group of Stocks

1

Our Expert Thinking

The $8 billion Paramount-Skydance merger approval signals a new wave of consolidation in Hollywood. This landmark deal creates competitive pressure that may force other media companies to pursue strategic partnerships and acquisitions to maintain their market position and scale.

2

What You Need to Know

This group includes a diverse mix of media and entertainment companies, from major content creators and broadcasters to specialized streaming technology and digital advertising firms. These stocks represent various segments of the entertainment industry that could benefit from increased M&A activity.

3

Why These Stocks

These companies were handpicked by professional analysts as potential acquisition targets or strategic partners in a rapidly consolidating media landscape. Each represents an opportunity to capitalize on event-driven volatility and merger activity within the entertainment sector.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+25.53%

Group Performance Snapshot

25.53%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 25.53% over the next year.

11 of 13

Stocks Rated Buy by Analysts

11 of 13 assets in this group are rated Buy by professional analysts.

1.5%

Group Growth

This group averaged a 1.5% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🎬

Merger Mania Momentum

The Paramount-Skydance deal is just the beginning. Industry experts predict more consolidation ahead as media companies scramble to compete with streaming giants and maintain market share.

💰

Acquisition Target Potential

These carefully selected companies could become attractive buyout candidates as larger players seek to expand their content libraries, technology capabilities, and market reach.

📈

Event-Driven Opportunities

M&A activity often creates significant stock price movements. Getting positioned before the next big media deal announcement could lead to substantial returns for savvy investors.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View all Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.